CeriBell (NASDAQ:CBLL) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

CeriBell (NASDAQ:CBLL) issued its quarterly earnings data on Monday. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04), FiscalAI reports. The company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.

Here are the key takeaways from CeriBell’s conference call:

• Q2 revenue rose 33% year over year to $28.1 million, accelerating from 29% growth in Q1, while the active account base increased by 32 to 712. Management cited strong same-store utilization and expects 2026 revenue of $114 million-$117 million, up from prior guidance of $112 million-$116 million.
• Gross margin reached a record 92%, helped by a $1.6 million tariff refund; excluding the refund, margin was still 89%. Ceribell expects margins to remain in the high-80% range, supported by supply-chain savings and expanded manufacturing in Vietnam.
• Ceribell plans to commercially launch its Delirium monitoring solution in Q4 2026 after favorable pilot feedback and CMS approval of an NTAP providing up to $2,171 in incremental reimbursement per qualified patient. Neonatal and pediatric products also received early purchase orders, although management expects these newer offerings to contribute more meaningfully in 2027.
• Operating expenses increased 37% year over year to $45.9 million, contributing to a net loss of $19.3 million, or $0.51 per share. The company continues to reinvest heavily in sales, R&D and platform development, and has not yet specified when it will achieve cash-flow breakeven.
• The company received FDA clearances for artifact-reduction and epileptiform-abnormality algorithms, as well as components of a next-generation hardware platform designed for video, ECG, longer-duration monitoring and full-montage EEG. Limited releases are planned before a broader 2027 launch, which management views as a potential expansion into additional patient populations and markets.

CeriBell Stock Up 2.6%

CBLL stock opened at $19.30 on Tuesday. CeriBell has a 1-year low of $10.85 and a 1-year high of $24.33. The business’s 50 day simple moving average is $18.55 and its 200 day simple moving average is $19.08. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $732.30 million, a PE ratio of -11.84 and a beta of 0.81.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: The FDA granted 510(k) clearance for two AI enhancements to CeriBell’s cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. The features are designed to help neurologists identify abnormal EEG patterns, reduce signal interference and review critical-care recordings more efficiently. The update expands the functionality of CeriBell’s existing point-of-care brain-monitoring system without requiring software downtime or installation. CeriBell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction
• Positive Sentiment: Second-quarter revenue rose to $28.1 million, exceeding the $27.28 million analyst consensus. Management maintained full-year 2026 revenue guidance of $114 million to $117 million, with the low end in line with consensus, suggesting continued demand for the company’s neurological monitoring platform. CeriBell Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings call highlighted the newly cleared AI tools and the company’s focus on improving clinical workflows and adoption of its point-of-care EEG system. The commercial benefit of the enhancements will depend on hospital uptake, clinical acceptance and the company’s ability to convert the technology into incremental revenue. CeriBell Q2 2026 Earnings Call Transcript
• Negative Sentiment: CeriBell reported a second-quarter loss of $0.51 per share, wider than the $0.45-$0.47 consensus range and worse than the $0.38 loss recorded a year earlier. The company remains unprofitable, increasing investor focus on operating leverage and the pace at which revenue growth can offset expenses. CeriBell Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Reported insider-trading data shows 44 open-market sales and no purchases over the past six months, including sales by senior executives. While such transactions may reflect personal or equity-compensation decisions, the lack of insider buying is a potential sentiment headwind.

Insider Activity

In related news, Director William W. Burke sold 2,207 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total value of $43,786.88. Following the transaction, the director owned 23,022 shares in the company, valued at approximately $456,756.48. This represents a 8.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Xingjuan Chao sold 39,000 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $19.90, for a total transaction of $776,100.00. Following the completion of the transaction, the chief executive officer directly owned 802,317 shares in the company, valued at approximately $15,966,108.30. This represents a 4.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 300,685 shares of company stock valued at $5,935,326. 17.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On CeriBell

A number of hedge funds have recently bought and sold shares of CBLL. nVerses Capital LLC bought a new position in shares of CeriBell in the fourth quarter worth $282,000. Engineers Gate Manager LP bought a new stake in CeriBell during the fourth quarter worth about $260,000. Price T Rowe Associates Inc. MD lifted its position in CeriBell by 15.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,051 shares of the company’s stock worth $331,000 after purchasing an additional 2,008 shares during the period. Royal Bank of Canada grew its stake in CeriBell by 10.8% during the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after buying an additional 1,514 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in CeriBell in the 4th quarter valued at about $261,000.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CBLL. Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. Canaccord Genuity Group decreased their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.